NATA - Nucleic Acid Therapy Accelerator
@natahub.org
Advancing the development of nucleic acid therapies and associated technologies through high-quality science, collaborations and interdisciplinary research
We are pleased that NATA’s work is featured on the cover of Nucleic Acid Therapeutics. The study benchmarks ModDetect antibodies for detecting PS and MOE modifications in ASOs. Congrats to our Biology team.
Cover shows stained 3D cell cultures.
Read the paper: www.liebertpub.com/doi/10.1177/...
Cover shows stained 3D cell cultures.
Read the paper: www.liebertpub.com/doi/10.1177/...
Characterizing Antibodies Targeting Antisense Oligonucleotide Phosphorothioate and 2′-O-Methoxyethyl Modifications for Intracellular Trafficking and Biodistribution Studies | Nucleic Acid Therapeutics
The efficacy of nucleic acid therapeutics (NATs) such as antisense oligonucleotides (ASOs) and small interfering RNAs relies on multiple stages of extra- and intracellular trafficking. Assessing uptak...
www.liebertpub.com
September 2, 2025 at 10:37 AM
We are pleased that NATA’s work is featured on the cover of Nucleic Acid Therapeutics. The study benchmarks ModDetect antibodies for detecting PS and MOE modifications in ASOs. Congrats to our Biology team.
Cover shows stained 3D cell cultures.
Read the paper: www.liebertpub.com/doi/10.1177/...
Cover shows stained 3D cell cultures.
Read the paper: www.liebertpub.com/doi/10.1177/...
🧬The latest issue of the NATA newsletter is here!
This issue features a new project on targeted delivery of ASOs for COL6-CMD, and an update from Manufacturing Challenge on their biocatalytic synthesis breakthrough.
Read more: mailchi.mp/natahub.org/...
Subscribe: mailchi.mp/natahub.org/...
This issue features a new project on targeted delivery of ASOs for COL6-CMD, and an update from Manufacturing Challenge on their biocatalytic synthesis breakthrough.
Read more: mailchi.mp/natahub.org/...
Subscribe: mailchi.mp/natahub.org/...
NATA quarterly newsletter Q2 2025
View this email in your browser
mailchi.mp
July 2, 2025 at 7:10 AM
🧬The latest issue of the NATA newsletter is here!
This issue features a new project on targeted delivery of ASOs for COL6-CMD, and an update from Manufacturing Challenge on their biocatalytic synthesis breakthrough.
Read more: mailchi.mp/natahub.org/...
Subscribe: mailchi.mp/natahub.org/...
This issue features a new project on targeted delivery of ASOs for COL6-CMD, and an update from Manufacturing Challenge on their biocatalytic synthesis breakthrough.
Read more: mailchi.mp/natahub.org/...
Subscribe: mailchi.mp/natahub.org/...
We’re excited to launch our new quarterly newsletter — aim to give you a closer look at the work we’re doing at NATA.
📩 Sign up here to receive future editions: mailchi.mp/natahub.org/...
📖 Read the latest edition: mailchi.mp/natahub.org/...
#NATA #Newsletter #HealthcareInnovation #ScienceUpdate
📩 Sign up here to receive future editions: mailchi.mp/natahub.org/...
📖 Read the latest edition: mailchi.mp/natahub.org/...
#NATA #Newsletter #HealthcareInnovation #ScienceUpdate
May 13, 2025 at 9:41 AM
We’re excited to launch our new quarterly newsletter — aim to give you a closer look at the work we’re doing at NATA.
📩 Sign up here to receive future editions: mailchi.mp/natahub.org/...
📖 Read the latest edition: mailchi.mp/natahub.org/...
#NATA #Newsletter #HealthcareInnovation #ScienceUpdate
📩 Sign up here to receive future editions: mailchi.mp/natahub.org/...
📖 Read the latest edition: mailchi.mp/natahub.org/...
#NATA #Newsletter #HealthcareInnovation #ScienceUpdate
🎉NATA’s work is featured in Nucleic Acid Therapeutics!
A new article, led by Rockland Immunochemicals, includes images from Inês Fial. The journal cover also features her images; re-designed by Peter Oliver!
Congratulations to our Biology team!
🔗Read the paper: www.liebertpub.com/doi/10.1089/...
A new article, led by Rockland Immunochemicals, includes images from Inês Fial. The journal cover also features her images; re-designed by Peter Oliver!
Congratulations to our Biology team!
🔗Read the paper: www.liebertpub.com/doi/10.1089/...
March 13, 2025 at 1:27 PM
🎉NATA’s work is featured in Nucleic Acid Therapeutics!
A new article, led by Rockland Immunochemicals, includes images from Inês Fial. The journal cover also features her images; re-designed by Peter Oliver!
Congratulations to our Biology team!
🔗Read the paper: www.liebertpub.com/doi/10.1089/...
A new article, led by Rockland Immunochemicals, includes images from Inês Fial. The journal cover also features her images; re-designed by Peter Oliver!
Congratulations to our Biology team!
🔗Read the paper: www.liebertpub.com/doi/10.1089/...
🌍Today is Rare Disease Day!
Here’s a reminder that with over 300 million people worldwide living with a rare disease—only 5% having approved treatments—there is still so much work to be done.
At NATA, we are committed to advancing nucleic acid therapies for rare diseases.
#RareDiseaseDay
Here’s a reminder that with over 300 million people worldwide living with a rare disease—only 5% having approved treatments—there is still so much work to be done.
At NATA, we are committed to advancing nucleic acid therapies for rare diseases.
#RareDiseaseDay
February 28, 2025 at 1:21 PM
🌍Today is Rare Disease Day!
Here’s a reminder that with over 300 million people worldwide living with a rare disease—only 5% having approved treatments—there is still so much work to be done.
At NATA, we are committed to advancing nucleic acid therapies for rare diseases.
#RareDiseaseDay
Here’s a reminder that with over 300 million people worldwide living with a rare disease—only 5% having approved treatments—there is still so much work to be done.
At NATA, we are committed to advancing nucleic acid therapies for rare diseases.
#RareDiseaseDay
NATA is now on Bluesky!🎉
We are a not-for-profit MRC Unit dedicated to advancing the development of nucleic acid therapies through high-quality science, interdisciplinary collaborations and translational research.
Stay tuned for updates, insights, and all the latest on our work.
We are a not-for-profit MRC Unit dedicated to advancing the development of nucleic acid therapies through high-quality science, interdisciplinary collaborations and translational research.
Stay tuned for updates, insights, and all the latest on our work.
February 28, 2025 at 1:15 PM
NATA is now on Bluesky!🎉
We are a not-for-profit MRC Unit dedicated to advancing the development of nucleic acid therapies through high-quality science, interdisciplinary collaborations and translational research.
Stay tuned for updates, insights, and all the latest on our work.
We are a not-for-profit MRC Unit dedicated to advancing the development of nucleic acid therapies through high-quality science, interdisciplinary collaborations and translational research.
Stay tuned for updates, insights, and all the latest on our work.